Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score \>= 10).

Trial Details

NCT ID
NCT07389629
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • QL1706 Combined With Lenvatinib
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntarily sign a written informed consent form (ICF).
  • Age at the time of enrollment is \>= 18 and under 80 years old, with no gender restrictions.
  • The physical fitness score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1;
  • Expected survival period \>= 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →